Brokerages predict that ArQule, Inc. (NASDAQ:ARQL) will announce earnings per share of ($0.10) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for ArQule’s earnings. ArQule posted earnings per share of ($0.08) during the same quarter last year, which suggests a negative year over year growth rate of 25%. The business is scheduled to report its next earnings results before the market opens on Wednesday, May 3rd.
According to Zacks, analysts expect that ArQule will report full-year earnings of ($0.44) per share for the current fiscal year. For the next year, analysts forecast that the business will report earnings of ($0.42) per share. Zacks’ EPS averages are a mean average based on a survey of research analysts that follow ArQule.
ArQule (NASDAQ:ARQL) last posted its earnings results on Tuesday, March 7th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.10). ArQule had a negative return on equity of 55.62% and a negative net margin of 296.69%. The business earned $1.19 million during the quarter, compared to analyst estimates of $1.20 million. During the same quarter last year, the firm earned ($0.05) earnings per share.
Separately, Zacks Investment Research upgraded shares of ArQule from a “sell” rating to a “hold” rating in a research report on Wednesday, March 8th.
A hedge fund recently raised its stake in ArQule stock. Renaissance Technologies LLC boosted its position in shares of ArQule, Inc. (NASDAQ:ARQL) by 1.4% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 2,017,600 shares of the biotechnology company’s stock after buying an additional 26,900 shares during the period. Renaissance Technologies LLC owned about 2.84% of ArQule worth $2,542,000 at the end of the most recent reporting period. 58.99% of the stock is owned by institutional investors.
Shares of ArQule (NASDAQ:ARQL) traded down 0.99% during midday trading on Tuesday, reaching $1.00. The company’s stock had a trading volume of 10,458 shares. ArQule has a 12 month low of $0.92 and a 12 month high of $2.17. The stock’s market capitalization is $71.14 million. The stock’s 50-day moving average is $1.12 and its 200 day moving average is $1.33.
ArQule, Inc is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug candidates, all of which are in targeted patient populations.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ArQule Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule Inc. and related companies with MarketBeat.com's FREE daily email newsletter.